Table 2 Demographic and clinical characteristics of active patients, inactive patients, and healthy controls at baseline
Active disease (n = 74) | Non active disease (n = 56) | Control group (n = 62) | p-value | |
|---|---|---|---|---|
Sex, female (n(%)) | 57.0 (77.0) | 46.0 (82.0) | 31.0 (50.0) | < 0.001 |
Age (yr), mean (SD) | 10.3 (5.7) | 10.7 (3.9) | 10.0 (5.0) | 0.764 |
Weight (kg), mean (SD) | 37.8 (19.4) | 40.6 (16.5) | 40.5 (20.9) | 0.634 |
Height (cm), mean (SD) | 147.7 (28.1) | 144.2 (21.4) | 142.5 (28.0) | 0.448 |
BMI (kg/m2), mean (SD) | 18.7 (3.7) | 19.3 (3.5) | 19.7 (4.7) | 0.380 |
BMI SDS, mean (SD) | -0.1 (1.1) | 0.01 (1.0) | 0.05 (1.3) | 0.650 |
Age of JIA onset (yr), median (range) | 4.6 (1.0–15.0) | 4.4 (1.0-14.5) | 0.388 | |
Disease duration (yr), mean (SD) | 4.3 (4.7) | 5.4 (3.8) | 0.012 | |
JIA categories (n(%)) | 0.794 | |||
• Oligoarticular | 44.0 (59.5) | 31.0 (55.4) | ||
• Extended oligoarticular | 9.0(12.2) | 10.0(17.9) | ||
• Polyarticular | 15.0(20.3) | (21.4) 12.0 | ||
• Psoriasic | 5.0 (6.8) | 3.0 (5.4) | ||
• Enthesitis-Arthritis | 1.0 (1.4) | 0.0 (0.0) | ||
Previous therapy (n, (%)) | 0.005 | |||
• None therapy or drug | 17.0 | 1.0 (1.8) | ||
• Methotrexate | 35.0 | 29.0(51.8) | ||
• Etanercept | 4.0(5.4) | 0.0 (0.0) | ||
• Adalimumab | 1.0 (1.4) (47.3) | 0.0 (0.0) | ||
• MTX + Etanercept | 7.0 (9.5) | 9.0 (16.1) | ||
• MTX + Adalimumab | 3.0 (4.1) | 3.0 (5.4) | ||
• MTX + Etanercept + Adalimumab | 1.0 (1.4) | 0.0 (0.0) | ||
• NSAIDs | 5.0 (6.8) | 12.0 (21.4) | ||
• Tocilizumab | 1.0 (1.4) | 2.0 (3.6) | ||
• Intra-articular corticosteroids | 44.0(59.5) | 48.0 (85.7) | ||
Number of previous intra-articular infiltrations, median (range) | 1.0 (0.0–15.0) | 1.0 (0.0–5.0) | 0.140 | |
Lag time to MTX initiation (yr), median (range) | 0.2 (0.0-6.2) | 0.3 (0.0-9.4) | 0.431 | |
MTX treatment duration (yr), median (range) | 0.7 (0.0-12.4) | 1.3 (0.0-6.9) | 0.068 | |
Lag time to biologic therapy initiation (yr), median (range) | 0.1 (0.0-8.6) | 0.3 (0.0-11.3) | 0.864 | |
Biologic therapy duration (yr), median (range) | 0.1 (0.0–13.0) | 0.7 (0.0–9.0) | 0.019 | |
On therapy (n(%)) | 53.0 (71.6) | 39.0 (69.6) | 0.523 | |
Ongoing therapy (n(%)) | 0.071 | |||
• No | 21.0 28.4) | 17 (30.3) | ||
• Methotrexate | 17.0(23.0) | 13.0 (23.2) | ||
• Etanercept | 10.0(13.5) | 12.0 (21.4) | ||
• Adalimumab | 12.0(16.2) | 14.0 (25.0) | ||
• MTX + Etanercept | 3.0 (4.1) | 0.0 (0.0) | ||
• MTX + Adalimumab | 3.0 (4.1) | 0.0 (0.0) | ||
• Other | 2.0 (2.7) | 0.0 (0.0) | ||
• NSAIDs | 6.0(8.1) | 0.0 (0.0) | ||
Number of involved joints at JIA onset, median (range) | 2.0 (1.0–15.0) | 2.0 (0.0–14.0) | 0.143 | |
History of uveitis (n(%)) | 16.0 (21.6) | 12.0 (21.4) | 0.678 | |
ANA positive+ (n(%)) | 56.0 (75.7) | 44.0 (78.6) | 0.432 | |
RF positive+ (n(%)) | 1.0 (1.4) | 2.0 (3.6) | < 0.001 | |
HLA-B27 positive+ (n(%)) | 2.0 (2.7) | 0.0 (0.0) | < 0.001 | |
JADAS 27, median (range) | 5.0 (0.5–20.0) | 0.0 (0.0-5.4) | < 0.001 |